News

Deeplex® Myc-TB: A high-performance targeted sequencing solution for rapid mycobacterial identification and tuberculosis drug resistance diagnosis Rapid diagnosis of mycobacterial infection and early detection of tuberculosis (TB) drug resistance are critical to guide prompt clinical decision-making and improving patient outcomes. A recent study published in the Journal of Clinical Microbiology

Deeplex® Myc-TB: Targeted sequencing improves clinical detection of tuberculosis drug resistance A recent study published in Nature Communications highlights the value of targeted next-generation sequencing (tNGS), using Deeplex® Myc-TB, in improving the clinical diagnosis of drug-resistant tuberculosis. Conducted within the national tuberculosis control programme in Eswatini, the study demonstrates that

Evaluation of the Deeplex® Myc-TB Assay: A major advance in mycobacterial diagnosis and drug resistance detection The rapid and accurate diagnosis of mycobacterial infections remains a major public health challenge. Distinguishing bacteria belonging to the Mycobacterium tuberculosis complex (MTBC), which causes tuberculosis, from nontuberculous mycobacteria (NTM) is essential for guiding

Advancing tuberculosis detection: From patient stories to innovative NGS solutions Tuberculosis remains one of the leading infectious diseases worldwide, requiring continuous innovation in detection and treatment. Behind the global fight against TB are both powerful human stories and groundbreaking scientific advances that are transforming patient care. A tuberculosis survivor’s story

Helicobacter pylori: a persistent carcinogenic threat amid a growing gastric cancer burden Helicobacter pylori, classified as a Group 1 carcinogen¹ by the World Health Organization, is the leading cause of gastric cancer, a disease associated with high morbidity and a frequently poor prognosis. Yet this chronic infection is largely preventable

Deeplex® Myc-TB: Cost-saving & cost-effective TB resistance detection A recent study conducted in South Africa demonstrates the clinical value and cost-effectiveness of targeted next-generation sequencing for tuberculosis drug resistance testing, using Deeplex Myc-TB. It demonstrates that this approach improves the speed and accuracy of diagnosis, optimizes treatment management, reduces infectiousness